- Nevro Corp (NYSE:NVRO) announced positive updates to multiple spinal cord stimulation (SCS) coverage policies.
- Aetna’s new SCS policy explicitly covers PDN (painful diabetic neuropathy), effective August 29, 2022. Aetna’s health plan covers approximately 22 million commercial lives.
- Novitas and First Coast also provided a positive update. They published draft local coverage determinations (LCDs) that proposed updated coverage criteria to include PDN.
- This includes PDN refractory to conventional medical management for SCS devices with explicit FDA approval to treat PDN.
- If finalized, the LCDs mean Medicare patients in all 50 states will receive coverage for PDN, adding approximately 17 million covered Medicare lives. The review for the proposed LCDs is ongoing, with finalization dates yet to be determined.
- Nevro said Aetna’s update adds to recent positive decisions from UnitedHealthcare, Blue Cross Blue Shield, and Noridian. Altogether, these decisions increase coverage in the U.S. to approximately 54% of PDN patients. That represents a rise from approximately 25% at the end of 2021. If the MAC policies pan out, coverage rises to approximately 66%.
- Price Action: NVRO shares are down 3.50% at $43.74 on the last check Thursday.
MariaDB Finalizes Spinoff Of SkySQL; Newly Formed Company SkySQL Inc. Acquires Rights To SkySQL Database-As-A-Service Product
Newly formed company SkySQL Inc. acquires rights to SkySQL database-as-a-service (DBaaS) productMariaDB plc (NYSE:MRDB) today announced that it has completed the spinoff of its SkySQL business to SkySQL Inc., a new
